Alpha 2.0
Login Register
» Authors » Mikhail Lichinitser

Mikhail Lichinitser

Explore the profile of Mikhail Lichinitser including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 20
Citations 6367
Followers 0
Related Specialties
Oncology
General Medicine
Biology
Top 10 Co-Authors
Vladimir Semiglazov
Christian Jackisch
Bohuslav Melichar
Dirk Schadendorf
Jim Cassidy
Felix Couture
Arie Figer
Ralph Wong
Eduardo Diaz-Rubio
Stephen Clarke
Published In
J Clin Oncol
Lancet Oncol
N Engl J Med
Eur J Cancer
Melanoma Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
Saltz L, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al.
J Clin Oncol . 2023 Jul; 41(21):3663-3669. PMID: 37459755
Purpose: To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid plus oxaliplatin [FOLFOX-4]) in patients with metastatic...
2.
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma
Eggermont A, Blank C, Mandala M, Long G, Atkinson V, Dalle S, et al.
Eur J Cancer . 2019 Jun; 116:148-157. PMID: 31200321
Background: The American Joint Committee on Cancer-8 (AJCC) classification of melanoma was implemented in January 2018. It was based on data gathered when checkpoint inhibitors were not used as adjuvant...
3.
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Eggermont A, Blank C, Mandala M, Long G, Atkinson V, Dalle S, et al.
N Engl J Med . 2018 Apr; 378(19):1789-1801. PMID: 29658430
Background: The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial to...
4.
HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up
Jackisch C, Hegg R, Stroyakovskiy D, Ahn J, Melichar B, Chen S, et al.
Eur J Cancer . 2016 May; 62:62-75. PMID: 27208905
Background: In the phase III, open-label, randomised HannaH study, fixed-dose neoadjuvant-adjuvant subcutaneous trastuzumab for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer was non-inferior to standard weight-based intravenous...
5.
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3,...
Grob J, Amonkar M, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, et al.
Lancet Oncol . 2015 Oct; 16(13):1389-98. PMID: 26433819
Background: In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were treated with the combination of dabrafenib and trametinib had significantly...
6.
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, et al.
Lancet Oncol . 2014 Mar; 15(6):640-7. PMID: 24657003
Background: In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH) trial in women with HER2-positive locally advanced or inflammatory breast cancer, neoadjuvant trastuzumab significantly improved pathological complete response rate...
7.
Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal...
Yardley D, Ismail-Khan R, Melichar B, Lichinitser M, Munster P, Klein P, et al.
J Clin Oncol . 2013 May; 31(17):2128-35. PMID: 23650416
Purpose: Entinostat is an oral isoform selective histone deacetylase inhibitor that targets resistance to hormonal therapies in estrogen receptor-positive (ER+) breast cancer. This randomized, placebo-controlled, phase II study evaluated entinostat...
8.
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)
Pestalozzi B, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, et al.
Lancet Oncol . 2013 Feb; 14(3):244-8. PMID: 23414588
Background: Several randomised trials have confirmed the benefit of adjuvant trastuzumab for patients with HER2-positive early breast cancer. However, concern has been expressed that adjuvant trastuzumab might be associated with...
9.
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim S, et al.
Lancet Oncol . 2012 Aug; 13(9):869-78. PMID: 22884505
Background: A subcutaneous formulation of trastuzumab has been developed, offering potential improvements in patient convenience and resource use compared with the standard intravenous infusion of the drug. We compared the...
10.
Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer
Martin M, Makhson A, Gligorov J, Lichinitser M, Lluch A, Semiglazov V, et al.
Oncologist . 2012 Apr; 17(4):469-75. PMID: 22467666
We report the first results from a phase II, open-label study designed to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab and capecitabine as first-line therapy for...